Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Shenzhen Stock Exchange 002940.SZ

Zhejiang AngLiKang Pharmaceutical CO.,LTD. Price to Book Ratio (P/B) on January 14, 2025: 1.65

Zhejiang AngLiKang Pharmaceutical CO.,LTD. Price to Book Ratio (P/B) is 1.65 on January 14, 2025, a -34.87% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Zhejiang AngLiKang Pharmaceutical CO.,LTD. 52-week high Price to Book Ratio (P/B) is 2.53 on January 15, 2024, which is 53.55% above the current Price to Book Ratio (P/B).
Zhejiang AngLiKang Pharmaceutical CO.,LTD. 52-week low Price to Book Ratio (P/B) is 1.49 on July 30, 2024, which is -9.45% below the current Price to Book Ratio (P/B).
Zhejiang AngLiKang Pharmaceutical CO.,LTD. average Price to Book Ratio (P/B) for the last 52 weeks is 1.86.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shenzhen Stock Exchange: 002940.SZ

Zhejiang AngLiKang Pharmaceutical CO.,LTD.

CEO	Mr. Nan Ping Fang
IPO Date	Oct. 23, 2018
Location	China
Headquarters	No. 1000, North of Shengzhou Avenue
Employees	1,290
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Zhejiang Anglikang Pharmaceutical Co., Ltd. engages in the production and sale of pharmaceutical materials, pharmaceutic preparations, and medical empty capsules. The company offers products in anti-infection, antihypertensive, digestive system, and respiratory preparation. It is also involved in research and development of drugs for featuring oral cephalosporins, cardiovascular, kidney, and central nervous diseases. The company was founded in 2001 and is based in Shengzhou, China.

Key trends

Past 5 years